

## **China Everbright Limited's portfolio company Eloxx Pharmaceuticals Starts Trading on the OTCB**

26 January 2018 – **China Everbright Limited** (“CEL”, stock code: 165.HK) is proud to announce that **Eloxx Pharmaceuticals Inc.** (OTCQB:ELOX, “Eloxx”), a portfolio company of the Catalyst-CEL China Israel Fund (“The Fund”), has begun trading as a public company on the OTCQB stock exchange, a US based Over-the-Counter exchange. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops molecule medicines to treat rare and ultra-rare genetic diseases caused by non-sense mutations.

Eloxx listed on the OTCQB on December 20<sup>th</sup> following the completion of a planned acquisition transaction with Sevion Therapeutics Inc.. The combined listed company will be known as Eloxx Pharmaceuticals Inc..

Eloxx has been running their first round of clinical trials for their read-through therapy drug ELX-02 since last November. The drug is designed to increase translation and restoring activity of the mutated proteins in genetic mutations.

Eloxx is headquartered in Waltham, Massachusetts, USA, with its R&D centre based in Rehovot, Israel. They are the fifth investment made by the Fund. “We are excited for Eloxx Pharmaceutical’s prospects going forward,” said Shengyan Fan, Managing Partner of the Fund and Head of Merger and Acquisition Department at CEL. “Eloxx is breaking new ground in the treatment for rare genetic diseases, and we are looking forward to seeing their development in the near future.” The OTCQB is a trading platform for venture companies to fulfil listing requirements as a public company before trading on larger platforms such as the NASDAQ and NYSE.

The Fund’s previous investments include Lamina Technologies, a manufacturer of state-of-the-art, precision carbide metal cutting tools; XJet, the world's pioneering technology of inkjet-based 3D printing system for metal and ceramic parts; Taboola, a leading Israeli-founded and US-based online content discovery platform, and SatixFy, a leading provider of satellite and quasi-satellite communication technology.

**About China Everbright Limited**

China Everbright Limited was established in Hong Kong in 1997. As a member of China Everbright Group, CEL is China's leading cross-border investment and asset management company. It manages private equity funds, venture capital funds, sector focus funds, mezzanine funds, fund of funds, fixed income and equity funds. CEL utilizes its strong capital strength and cultivates a number of high-growth-potential enterprises together with its investors. While closely following the development requirements of Chinese companies, it also seamlessly merges the best in overseas technologies with the Chinese market, providing diversified financial services for its Chinese clients involved in overseas investment. At the end of June 2017, CEL managed 38 funds with fundraising scale of HKD 106.6 billion.

**About Catalyst-CEL China Israel Fund**

The Catalyst-CEL Fund, jointly managed by China Everbright Limited and Catalyst Investments (Israel) III Ltd, primarily targets Israeli and Israeli related mid-to-late stage companies with record of innovation and global presence, and whose strategy of expanding is aiming or including expansion of activities into the Greater China market especially, and emerging markets in general, or companies who produce products or provide business solutions that have a significant commercial potential in the above mentioned market.

**About Eloxx Pharmaceuticals**

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. Nonsense mutations are a class of genetic defects that result in premature termination of protein synthesis. These nonsense mutations have been identified in over 2,000 rare and ultra-rare diseases. As a consequence, patients with a genetic disease caused by nonsense mutations have absent or truncated nonfunctional proteins, accounting for some of the most severe phenotypes in these genetic diseases. Eloxx's lead product candidate, ELX-02, is an investigational, novel translational read-through inducing drug designed to restore synthesis of full-length functional proteins. ELX-02 is an investigational agent undergoing clinical trials and has not been approved by any global regulatory body. Eloxx was founded in 2013 and is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.

**For further information, please contact:**

Shengyan Fan  
Managing Director  
China Everbright Limited  
[fan.shengyan@everbright.com](mailto:fan.shengyan@everbright.com)  
Office: +852 2905 0860

Barbara Ryan  
Investor Relations  
Eloxx Pharmaceutical Inc.  
[barbarar@eloxxpharma.com](mailto:barbarar@eloxxpharma.com)  
Office: +203 274 2825